Benjamin H. Lowentritt

Dr. Benjamin H. Lowentritt


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Advances in Radiation Oncology
Verified
Journal Article
Open access
BLBenjamin H. Lowentritt
Benjamin H. Lowentritt
AJAshesh B. Jani
Ashesh B. Jani
BHBrian T. Helfand
Brian T. Helfand
EUEdward M. Uchio
Edward M. Uchio
MMMichael A. Morris
Michael A. Morris
DSDavid M. Schuster
David M. Schuster
18F-Flotufolastat (18F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated 18F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on 18F-flotufolastat detection rates (DR). The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on 18F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratified according to the patients’ prior treatment (radical prostatectomy ± radiation therapy [RP] or radiation therapy only [RT]). The patients underwent positron emission tomography 50 to 70 minutes after receiving 18F-flotufolastat (296 MBq IV), and scans were read by 3 blinded central readers, with the majority read representing agreement between ≥2 readers. In total, 389 men (median PSA: 1.10 ng/mL) were evaluable. By majority read, 18F-flotufolastat identified distant lesions in 39% and 43% of patients treated with prior RP or RT, respectively. The overall DR broadly increased with increasing PSA (<0.2 ng/mL: 33%; ≥10 ng/mL: 100%). Among patients with PSA <1 ng/mL, 68% had positive scans, and 27% had extrapelvic findings. PSAdt was available for 145/389 (37%) patients. PSAdt did not appear to influence 18F-flotufolastat DR (77%-90% across all PSAdt categories). Among patients with prior RP, DR ranged from 70% to 83% across PSAdt categories, and 100% DR was reported for all post-RT patients. In total, 362/389 (93%) patients had baseline GG data. Overall DRs were uniformly high (75%‒95%) across all GG. When stratified by prior treatment, DRs across all GG were 69% to 89% in patients with prior RP and ≥96% in patients with prior RT. 18F-Flotufolastat-positron emission tomography enabled the accurate detection of recurrent PCa lesions across a wide range of PSA, PSAdt, and International Society of Urologic Pathology GG, thus supporting its clinical utility for a broad range of patients with recurrent PCa.

14 February 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BLBenjamin H. Lowentritt
Benjamin H. Lowentritt
ACAlbert Chau
Albert Chau
PDPhillip Davis
Phillip Davis
Objectives: To explore the impact of different standard of truth (SoT) methodologies on efficacy endpoints traditionally used in clinical trials of diagnostic radiopharmaceuticals, using data from the SPOTLIGHT study (NCT04186845) in patients with recurrent prostate cancer. Methods: Data from patients with baseline prostate-specific antigen (PSA) ≤ 5 ng/mL, who underwent 18F-flotufolastat imaging and had data for SoT determination, were reviewed. Majority-read patient level endpoints (verified detection rate [VDR] and patient-level positive predictive value [PPV]), and region-level PPV (in the prostate/prostate bed, pelvic lymph nodes, and extrapelvic sites) according to on-study reads by three blinded readers, were stratified by the SoT methodology (histopathology; post-PET confirmatory imaging; baseline/historic conventional imaging) used by the independent Truth Panel to verify 18F-flotufolastat-avid lesions. Differences between SoT groups for each endpoint were compared using a chi-square test (statistically significant if p < 0.0167). Results: Our analysis included 297 patients (median baseline PSA = 0.8 ng/mL): 56% (n = 166) had post-PET confirmatory imaging, 26% (n = 78) had baseline/historic conventional imaging, and 18% (n = 53) had histopathological confirmation of ≥1 PET-positive lesion. For all endpoints assessed, the highest majority-read values were achieved with histopathology SoT. For histopathology versus baseline/historic conventional imaging, VDR (77%) was 3.6-fold higher (p < 0.0001), patient-level PPV (79%) was 2.2-fold higher (p < 0.0001), and region-level PPV (50%) was 3.7-fold higher in the prostate/prostate bed (p = 0.009); smaller increases were seen in majority-read PPV in the pelvic lymph nodes (77%; 1.5-fold) and other sites (75%; 1.3-fold), but these were not of statistical significance. Conclusions: These data illustrate how SoT methods can substantially impact efficacy endpoints traditionally used in clinical trials of diagnostic radiopharmaceuticals. Notably lower endpoint values are achieved with imaging SoT than with histopathology.

1 September 2025 in Urology Practice
Verified
Journal Article
Open access
BLBenjamin H. Lowentritt
Benjamin H. Lowentritt
SASreevalsa Appukkuttan
Sreevalsa Appukkuttan
NLNicholas Lazarou
Nicholas Lazarou
LOLorraine O’dOnnell
Lorraine O’dOnnell
JEJames Eller
James Eller
JHJoelle Hamilton
Joelle Hamilton
This study examines patient clinical profiles and real-world utilization patterns of darolutamide doublet (+ADT alone) and triplet therapy (+ADT and docetaxel) for the treatment of metastatic hormone-sensitive prostate cancer. This was a retrospective, observational study using the Precision Point Specialty Analytics (Specialty Networks) patient population health management platform to identify adult men with metastatic hormone-sensitive prostate cancer who received darolutamide doublet or triplet therapy between July 1, 2019, and March 31, 2023. Of 420 patients, 249 received doublet therapy and 171 received triplet therapy. Most patients included in the analysis were non-Hispanic White (doublet therapy: 67.1%; triplet therapy: 63.2%) and had Medicare insurance (doublet therapy: 77.5%; triplet therapy: 54.4%). Comorbid conditions were common, with hypertension (32.4%) and diabetes (15.0%) being the most prevalent. The mean prostate-specific antigen value at the index date was 20.9 ng/mL (standard deviation 87.2 ng/mL) in the doublet therapy cohort and 66.4 ng/mL (standard deviation 286.4 ng/mL) in the triplet therapy cohort. Most patients presented with high-grade cancer at diagnosis, with 50.6% of patients in the doublet therapy cohort and 74.2% of patients in the triplet therapy cohort having a high (≥8) Gleason score at diagnosis. The median duration of darolutamide treatment in the doublet therapy cohort was 48 weeks and in the triplet therapy cohort was 46 weeks. This study demonstrated that darolutamide doublet therapy and triplet therapy are used ubiquitously across community urology practices in the United States for the treatment of metastatic hormone-sensitive prostate cancer.


27 August 2025 in Research Square
Verified
Preprint
Open access
PDF file
MFMichael Fabrizio
Michael Fabrizio
PMPaul Monk
Paul Monk
PSPaul Sieber
Paul Sieber
JHJason Hafron
Jason Hafron
LKLawrence Karsh
Lawrence Karsh
NSNeil Shore
Neil Shore
Background Sipuleucel-T, approved for metastatic castration-resistant prostate cancer (mCRPC) in 2010, improves survival, but real-world outcomes data are limited. We compared baseline characteristics and real-world overall survival (rwOS) of patients treated with and without sipuleucel-T for mCRPC. Methods This multicenter, retrospective observational study analyzed electronic medical records from United States community urology clinics. Men aged ≥ 18 years diagnosed with mCRPC between January 2010 and May 2019 were divided into 2 groups based on whether they received sipuleucel-T. Propensity score matching (PSM) was used to balance the cohorts by age, race, region, prostate-specific antigen (PSA) level, and Gleason score. Results Among 11 265 patients, 47% received sipuleucel-T. They were younger, had lower PSA levels, and better performance scores than those who did not receive it. Median follow-up was 3 years for treated and 1 year for untreated patients. Sipuleucel-T recipients had markedly better 5-year survival rates (28% vs 12%) and lived a median of 20 months longer (44 vs 24 months; P < .001). Black/African American patients had the highest 5-year survival (24%) compared with White (20%) or other groups (17%). After PSM, the median rwOS was 43 months with sipuleucel-T and 25 months without it, with an 18-month survival advantage (hazard ratio 1.66; 95% CI 1.54–1.78). Conclusions Sipuleucel-T was associated with significantly improved mCRPC survival in real-world settings, especially among Black/African American patients. Findings are subject to limitations, including selection bias and unmeasured confounding, but reinforce the therapeutic and life-prolonging benefit of sipuleucel-T.

14 June 2026 in Prostate International
Verified
Journal Article
Open access
Elena CastroElena Castro
Elena Castro
JCJie-Fu Chen
Jie-Fu Chen
BLBenjamin H. Lowentritt
Benjamin H. Lowentritt
PDPartha Das
Partha Das
RDRamin Dowlati
Ramin Dowlati
DODavid Olmos
David Olmos